Chamber and committees

The term “puberty-suppressing hormones” is non-specific, and could be applied to a range of medicines used for a variety of conditions.

The Scottish Government and NHS Scotland are proactively engaged with NHS England and its commissioned research study on puberty-suppressing hormones as a treatment option for gender dysphoria. This is being delivered by the National Institute for Health Research (NIHR). The Scottish Government and the NHS in Scotland are currently observers to that ongoing study development process, however consideration by NHS partners of what further engagement with this study may be appropriate is ongoing, as the scope of the research continues to be developed and defined by NIHR.

The National Gender Identity Healthcare Reference Group continues to meet and make progress against all the commitments set out within the referenced December 2021 Strategic Action Framework. This includes:

• Healthcare Improvement Scotland developing standards for gender identity healthcare for NHS Scotland;
• NHS Education Scotland developing a Transgender Health Knowledge and Skills framework for NHS staff;
• Public Health Scotland working with Health Boards to deliver publication of waiting times data by them; and
• Grant funding to the University of Glasgow to administer a programme of research on gender identity healthcare.

Decisions on clinical pathways are not for the Scottish Government. These decisions are for clinicians, based on the best evidence available, through the appropriate clinical governance structures.

On 18 April, in a joint statement, NHS Greater Glasgow and Clyde and NHS Lothian confirmed that both Boards have paused any new prescription of puberty-supressing hormones and cross-sex hormones for young people as a treatment option for gender dysphoria.

The small number of patients directly impacted by this change, and their families, were notified in advance of this statement. It is right that they were the first to hear about it, sensitively and from the services caring for them, before a public statement was made.

The Scottish Government understands that Public Health Scotland intends to publish, as official statistics in development, gender identity clinic waiting times information provided by NHS Grampian, NHS Greater Glasgow and Clyde, NHS Highland and NHS Lothian in late summer 2024. This will be subject to the necessary data quality and completeness standards being met.

I refer the member to the answer to question S6W-26406 on 19 April 2024. All answers to written Parliamentary Questions are available on the Parliament's website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers .

Decisions on clinical pathways are not for the Scottish Government. These decisions are for clinicians, based on the best evidence available, through the appropriate clinical governance structures.

On 18 April, in a joint statement, NHS Greater Glasgow and Clyde and NHS Lothian confirmed that both Boards have paused any new prescription of puberty-supressing hormones and cross-sex hormones for young people as a treatment option for gender dysphoria.

The small number of patients directly impacted by this change, and their families, were notified in advance of this statement. It is right that they were the first to hear about it, sensitively and from the services caring for them, before a public statement was made.

Scottish Government has confirmed funding for the Workforce Specialist Service (WSS) for 2024-25 and the current contract will be extended for a further 12 months. WSS provides confidential mental health assessment and treatment for regulated health, social care and social work professionals in Scotland.

The Digital Prescribing and Dispensing Pathways (DPDP) programme, is scheduled to replace the current paper prescription in Scotland with a digital approach by the end of this parliamentary term.

The business case which sets out the proposal for the next phase, and associated funding, for the programme are currently under consideration.

We do not know the numbers of children affected because the information has not been collected historically.

In response to the Independent Medicines and Medical Devices Safety Review (IMMDSR), the Scottish Government commissioned Public Health Scotland (PHS) to establish a medicines in pregnancy surveillance asset. This resource will support monitoring and reporting to progress improvements in the safe use of valproate and other teratogenic medicines in Scotland. Its first output is due to be published by PHS in April 2024 and will include prescribing data and trends for valproate and other anti-seizure medicines.

The Scottish Fire and Rescue Service (SFRS) naloxone programme was launched in February 2022, backed with investment of £89,000 from Scottish Government. The programme aims to establish a network of fire officers who will carry naloxone and be trained to administer it in the event of an emergency.

Since then, all SFRS staff have been invited to complete online training to learn more about drug deaths in Scotland and how naloxone can help someone in the event of an opioid overdose. To date, 3,379 out of all 7,619 staff have voluntarily completed the training.

There is additional training for Flexi Duty Officers (FDOs) who have volunteered to carry naloxone and there are now 31 trained FDO volunteers within SFRS who are able to do this. It is expected that over the next 6 weeks a further 130 FDO volunteers will be trained and equipped to carry and administer naloxone.

The carrying and administering Naloxone is considered by the Fire Brigades Union (FBU) to be a form of emergency medical response which currently sits out-with the role map of firefighters. SFRS has a desire to broaden the role of firefighters which would incorporate emergency medical response but this is dependent on reaching agreement with the FBU.

SFRS and Scottish Government are determined to fully implement this programme and will continue to work closely with all parties, including representative bodies, to overcome any barriers to its full implementation.